Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance

Can a noninvasive urine methylation assay accurately detect urothelial carcinoma and facilitate postoperative recurrence surveillance? In this diagnostic study including a training cohort of 643 participants and a multicenter validation cohort of 1620 participants, a noninvasive urine-based assay targeting AL021918.2 and VIM methylation achieved 90.8% sensitivity and 93.2% specificity for urothelial carcinoma detection. In a longitudinal surveillance cohort, the assay identified all 9 observed recurrences and provided a median lead time of 4.5 months before clinical confirmation. This methylation assay may serve as a complementary noninvasive approach for urothelial carcinoma detection and postoperative recurrence surveillance.

Corresponding Authors: Xuesong Li, MD (pineneedle@sina.com), and Yanqing Gong, PhD (yqgong@bjmu.edu.cn), Department of Urology, Peking University First Hospital, No. 8, Xishiku St, Xicheng, Beijing 100034, China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.